anti-MAGEA4 TCR, pMX-IRES-GFP(TCR-L063)
The vector of anti-MAGEA4 T cell receptor (TCR) is constructed for the engineering of T cell to target Human MAGEA4. The T cells are genetically modified through transduction with a retroviral vector expressing MAGEA4-specific T cell receptor. And the vector product was designed for the treatment of Esophageal cancer, a head and neck cancer, a non-small cell pulmonary cancer, a stomach cancer and Hodgkin's disease.
Esophageal cancer, a head and neck cancer, a non-small cell pulmonary cancer, a stomach cancer and Hodgkin's disease
MAGE family member A4
CT1.4; MAGE4; MAGE4A; MAGE4B; MAGE-41; MAGE-X2; TCR; T cell receptor; transgenic TCR; antigen-specific T cell receptors; Engineering T-cell receptors; recombinant t cell receptors; specific t cell receptor; modified t cell receptor; retroviral vector; Esophageal cancer; head and neck cancer; non-small cell pulmonary cancer; stomach cancer; Hodgkin's disease
This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. At least four variants encoding the same protein have been found for this gene.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.